KR100886854B1 - Ｎ-페닐아릴설폰아미드 화합물, 이 화합물을 유효성분으로서 함유하는 약제, 이 화합물의 합성 중간체 및이의 제조 방법 - Google Patents
Ｎ-페닐아릴설폰아미드 화합물, 이 화합물을 유효성분으로서 함유하는 약제, 이 화합물의 합성 중간체 및이의 제조 방법 Download PDFInfo
- Publication number
- KR100886854B1 KR100886854B1 KR1020037011921A KR20037011921A KR100886854B1 KR 100886854 B1 KR100886854 B1 KR 100886854B1 KR 1020037011921 A KR1020037011921 A KR 1020037011921A KR 20037011921 A KR20037011921 A KR 20037011921A KR 100886854 B1 KR100886854 B1 KR 100886854B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- amino
- isobutyl
- thiazolylsulfonyl
- benzoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)CN(c(cc(C)c(C)c1)c1OCc(cc1)ccc1-c1nnn[n]1)S(c1ccc(*)[o]1)(=O)=O Chemical compound CC(C)CN(c(cc(C)c(C)c1)c1OCc(cc1)ccc1-c1nnn[n]1)S(c1ccc(*)[o]1)(=O)=O 0.000 description 5
- IIAPELGCCZWGNZ-OUKQBFOZSA-N CC(C)CN(CS(C=O)(c1ccc(C)[o]1)=O)c(cc(CCC1)c1c1)c1OCc1ccc(/C=C/C(O)=O)cc1 Chemical compound CC(C)CN(CS(C=O)(c1ccc(C)[o]1)=O)c(cc(CCC1)c1c1)c1OCc1ccc(/C=C/C(O)=O)cc1 IIAPELGCCZWGNZ-OUKQBFOZSA-N 0.000 description 1
- OPWCBDYYHNBEOO-UHFFFAOYSA-N CC(C)CN(c(cc(C)c(C)c1)c1OCc(cc1)c(C)cc1-c1nnn[nH]1)S(c1ccccn1)(=O)=O Chemical compound CC(C)CN(c(cc(C)c(C)c1)c1OCc(cc1)c(C)cc1-c1nnn[nH]1)S(c1ccccn1)(=O)=O OPWCBDYYHNBEOO-UHFFFAOYSA-N 0.000 description 1
- KCQYMOMXHMMIEI-UHFFFAOYSA-N CC(C)CN(c(cc(C)c(C)c1)c1OCc(cc1)c(C)cc1-c1nnn[nH]1)S(c1nc(C)c[s]1)(=O)=O Chemical compound CC(C)CN(c(cc(C)c(C)c1)c1OCc(cc1)c(C)cc1-c1nnn[nH]1)S(c1nc(C)c[s]1)(=O)=O KCQYMOMXHMMIEI-UHFFFAOYSA-N 0.000 description 1
- ZCFHRMQLXFMEBJ-UHFFFAOYSA-N CC(C)CN(c(cc(C)c(C)c1)c1OCc(ccc(C(O)=O)c1)c1Cl)S(c1ccc(C)[o]1)(=O)=O Chemical compound CC(C)CN(c(cc(C)c(C)c1)c1OCc(ccc(C(O)=O)c1)c1Cl)S(c1ccc(C)[o]1)(=O)=O ZCFHRMQLXFMEBJ-UHFFFAOYSA-N 0.000 description 1
- MKUCVKNNOZQFIC-UHFFFAOYSA-N CC(C)CN(c(cc(C)c(C)c1)c1OCc(ccc(C(O)=O)c1)c1OC)S(c1nc(C)c[s]1)(=O)=O Chemical compound CC(C)CN(c(cc(C)c(C)c1)c1OCc(ccc(C(O)=O)c1)c1OC)S(c1nc(C)c[s]1)(=O)=O MKUCVKNNOZQFIC-UHFFFAOYSA-N 0.000 description 1
- BJSOJFPJSSHZQY-UHFFFAOYSA-N CC(C)CN(c(cc(C)c(Cl)c1)c1OCc(ccc(C(O)=O)c1)c1Cl)S(c1ccc(C)[o]1)(=O)=O Chemical compound CC(C)CN(c(cc(C)c(Cl)c1)c1OCc(ccc(C(O)=O)c1)c1Cl)S(c1ccc(C)[o]1)(=O)=O BJSOJFPJSSHZQY-UHFFFAOYSA-N 0.000 description 1
- RCLVSQKFUQWWTO-UHFFFAOYSA-N CC(C)CN(c(cc(C)c(Cl)c1)c1OCc(ccc(C(O)=O)c1)c1Cl)S(c1nc(C)c[s]1)(=O)=O Chemical compound CC(C)CN(c(cc(C)c(Cl)c1)c1OCc(ccc(C(O)=O)c1)c1Cl)S(c1nc(C)c[s]1)(=O)=O RCLVSQKFUQWWTO-UHFFFAOYSA-N 0.000 description 1
- CNVNWXNRYZNWHO-ACCUITESSA-N CC(C)CN(c(cc(C)cc1)c1OCc1ccc(/C=C/C(O)=O)cc1)S(c1ccc[o]1)(=O)=O Chemical compound CC(C)CN(c(cc(C)cc1)c1OCc1ccc(/C=C/C(O)=O)cc1)S(c1ccc[o]1)(=O)=O CNVNWXNRYZNWHO-ACCUITESSA-N 0.000 description 1
- KGUBUEWKWJFEDU-UHFFFAOYSA-N CC(C)CN(c(cc(CCC1)c1c1)c1OCc(cc1)ccc1C(O)=O)[S](C)(c1ccc(C)[o]1)(=O)=O Chemical compound CC(C)CN(c(cc(CCC1)c1c1)c1OCc(cc1)ccc1C(O)=O)[S](C)(c1ccc(C)[o]1)(=O)=O KGUBUEWKWJFEDU-UHFFFAOYSA-N 0.000 description 1
- ROYHRQSUMVOLSI-UHFFFAOYSA-N CC(C)N(c(cc(C)c(C)c1)c1OCc(cc1)c(C)cc1C(O)=O)S(c1ccc(C)[o]1)(=O)=O Chemical compound CC(C)N(c(cc(C)c(C)c1)c1OCc(cc1)c(C)cc1C(O)=O)S(c1ccc(C)[o]1)(=O)=O ROYHRQSUMVOLSI-UHFFFAOYSA-N 0.000 description 1
- BHVSBVVACASXJO-VAWYXSNFSA-N CC(C)N(c(cc(C)c(Cl)c1)c1OCc1ccc(/C=C/C(O)=O)cc1)S(c1ccccn1)(=O)=O Chemical compound CC(C)N(c(cc(C)c(Cl)c1)c1OCc1ccc(/C=C/C(O)=O)cc1)S(c1ccccn1)(=O)=O BHVSBVVACASXJO-VAWYXSNFSA-N 0.000 description 1
- RIQMXNBLDRHZKV-UHFFFAOYSA-N CC(C)N(c(cc(CCC1)c1c1)c1OCc(cc1)ccc1C(O)=O)S(c1nc(C)c[s]1)(=O)=O Chemical compound CC(C)N(c(cc(CCC1)c1c1)c1OCc(cc1)ccc1C(O)=O)S(c1nc(C)c[s]1)(=O)=O RIQMXNBLDRHZKV-UHFFFAOYSA-N 0.000 description 1
- YFVATGYHSZATIM-UHFFFAOYSA-N CC(C)N(c(cc(c(C)c1)Cl)c1OCc(cc1)ccc1C(O)=O)S(c1ncc[s]1)(=O)=O Chemical compound CC(C)N(c(cc(c(C)c1)Cl)c1OCc(cc1)ccc1C(O)=O)S(c1ncc[s]1)(=O)=O YFVATGYHSZATIM-UHFFFAOYSA-N 0.000 description 1
- KKBGTYPZPQQXFQ-UHFFFAOYSA-N CC(C)N(c(cc(c(C)c1)Cl)c1OCc(ccc(C(O)=O)c1)c1Cl)S(c1nc(C)c[s]1)(=O)=O Chemical compound CC(C)N(c(cc(c(C)c1)Cl)c1OCc(ccc(C(O)=O)c1)c1Cl)S(c1nc(C)c[s]1)(=O)=O KKBGTYPZPQQXFQ-UHFFFAOYSA-N 0.000 description 1
- KKRYPVMGMFRHFA-UHFFFAOYSA-N CC(C)N(c(ccc(C(F)(F)F)c1)c1OCc(cc1)ccc1C1=NNNN1)S(c1nc(C)c[s]1)(=O)=O Chemical compound CC(C)N(c(ccc(C(F)(F)F)c1)c1OCc(cc1)ccc1C1=NNNN1)S(c1nc(C)c[s]1)(=O)=O KKRYPVMGMFRHFA-UHFFFAOYSA-N 0.000 description 1
- ZXNAMCPUBJESFS-UHFFFAOYSA-N CC(CN(c(cc(CCC1)c1c1)c1OCc(cc1)ccc1C(O)=O)S(c1nc(C)c[s]1)(=O)=O)=C Chemical compound CC(CN(c(cc(CCC1)c1c1)c1OCc(cc1)ccc1C(O)=O)S(c1nc(C)c[s]1)(=O)=O)=C ZXNAMCPUBJESFS-UHFFFAOYSA-N 0.000 description 1
- UHJZALVJXBRXPI-UHFFFAOYSA-N CCCN(c(cc(CCC1)c1c1)c1OCc(cc1)c(C)cc1C(O)=O)S(c1ccc(C)[o]1)(=O)=O Chemical compound CCCN(c(cc(CCC1)c1c1)c1OCc(cc1)c(C)cc1C(O)=O)S(c1ccc(C)[o]1)(=O)=O UHJZALVJXBRXPI-UHFFFAOYSA-N 0.000 description 1
- OOQGRZMXOGHYEC-UHFFFAOYSA-N CCN(CC(C(C=O)=O)c1nc(C)c[s]1)C1C(OCc(cc2)ccc2C(O)=O)=CC(CCC2)=C2C1 Chemical compound CCN(CC(C(C=O)=O)c1nc(C)c[s]1)C1C(OCc(cc2)ccc2C(O)=O)=CC(CCC2)=C2C1 OOQGRZMXOGHYEC-UHFFFAOYSA-N 0.000 description 1
- KBHBAZRIEJBAFJ-UHFFFAOYSA-N CCN(c(cc(CCC1)c1c1)c1OCc(cc1)c(C)cc1C(O)=O)S1(CC1)(c1ccc(C)[o]1)=O Chemical compound CCN(c(cc(CCC1)c1c1)c1OCc(cc1)c(C)cc1C(O)=O)S1(CC1)(c1ccc(C)[o]1)=O KBHBAZRIEJBAFJ-UHFFFAOYSA-N 0.000 description 1
- XIZKKINTXKVNNI-UHFFFAOYSA-N Cc([o]1)ccc1S(N(CC1CC1)c(cc(CCC1)c1c1)c1OCc(cc1)c(C)cc1C(O)=O)(=O)=O Chemical compound Cc([o]1)ccc1S(N(CC1CC1)c(cc(CCC1)c1c1)c1OCc(cc1)c(C)cc1C(O)=O)(=O)=O XIZKKINTXKVNNI-UHFFFAOYSA-N 0.000 description 1
- CDRBZLXGVXIDJL-UHFFFAOYSA-N OC(c1ccc(COc(cc(c(Cl)c2)Cl)c2NS(c2ccccc2)(=O)=O)cc1)=O Chemical compound OC(c1ccc(COc(cc(c(Cl)c2)Cl)c2NS(c2ccccc2)(=O)=O)cc1)=O CDRBZLXGVXIDJL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2001-00068498 | 2001-03-12 | ||
| JP2001068498 | 2001-03-12 | ||
| JPJP-P-2001-00281569 | 2001-09-17 | ||
| JP2001281569 | 2001-09-17 | ||
| JP2002007760 | 2002-01-16 | ||
| JPJP-P-2002-00007760 | 2002-01-16 | ||
| PCT/JP2002/002245 WO2002072564A1 (en) | 2001-03-12 | 2002-03-11 | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20030082978A KR20030082978A (ko) | 2003-10-23 |
| KR100886854B1 true KR100886854B1 (ko) | 2009-03-05 |
Family
ID=27346214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020037011921A Expired - Fee Related KR100886854B1 (ko) | 2001-03-12 | 2002-03-11 | Ｎ-페닐아릴설폰아미드 화합물, 이 화합물을 유효성분으로서 함유하는 약제, 이 화합물의 합성 중간체 및이의 제조 방법 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7235667B2 (https=) |
| EP (2) | EP1369419B1 (https=) |
| JP (3) | JP3555620B2 (https=) |
| KR (1) | KR100886854B1 (https=) |
| CN (1) | CN1294126C (https=) |
| AT (2) | ATE522513T1 (https=) |
| AU (1) | AU2002238855B2 (https=) |
| BR (1) | BR0208027A (https=) |
| CA (1) | CA2439604C (https=) |
| CZ (1) | CZ304035B6 (https=) |
| DE (1) | DE60220255T2 (https=) |
| DK (2) | DK1369419T3 (https=) |
| ES (1) | ES2286230T3 (https=) |
| HU (1) | HU230056B1 (https=) |
| IL (2) | IL157701A0 (https=) |
| MX (1) | MXPA03008134A (https=) |
| NO (1) | NO329682B1 (https=) |
| NZ (1) | NZ528120A (https=) |
| PL (1) | PL218750B1 (https=) |
| PT (2) | PT1369419E (https=) |
| RU (1) | RU2299202C2 (https=) |
| TW (1) | TWI317359B (https=) |
| WO (1) | WO2002072564A1 (https=) |
| ZA (1) | ZA200306884B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022549A1 (ja) * | 2002-09-09 | 2004-03-18 | Ono Pharmaceutical Co., Ltd. | ４−メチル−１，３−チアゾール−２−イルスルホニルハライドの製造方法 |
| ES2308139T3 (es) * | 2003-01-29 | 2008-12-01 | Asterand Uk Limited | Antagonista de receptos ep4. |
| GB0317500D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Treatment of bph |
| EP1642594A1 (en) * | 2003-06-27 | 2006-04-05 | Ono Pharmaceutical Co., Ltd. | Remedy for urinary tract diseases |
| GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| JPWO2006004115A1 (ja) * | 2004-07-05 | 2008-04-24 | 中外製薬株式会社 | 過活動膀胱治療剤 |
| JP2008189549A (ja) * | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
| JP2009057282A (ja) * | 2005-12-19 | 2009-03-19 | Astellas Pharma Inc | カルボン酸誘導体又はその塩 |
| TW200817319A (en) * | 2006-08-10 | 2008-04-16 | Astellas Pharma Inc | Sulfonamide compound or salt thereof |
| AU2008215431C1 (en) | 2007-02-16 | 2013-10-17 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for urinary excretion disorder |
| DK2177512T3 (da) * | 2007-08-01 | 2012-06-18 | Taisho Pharmaceutical Co Ltd | S1P1-bindingshæmmer |
| JP2010043063A (ja) * | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
| JP5304785B2 (ja) * | 2008-06-23 | 2013-10-02 | アステラス製薬株式会社 | スルホンアミド化合物又はその塩 |
| TW201107309A (en) * | 2009-07-27 | 2011-03-01 | Kissei Pharmaceutical | Indole derivatives, or the pharmaceutically acceptable salts |
| CN103209960A (zh) * | 2010-07-26 | 2013-07-17 | 百时美施贵宝公司 | 用作cyp17抑制剂的磺酰胺化合物 |
| JP5363636B2 (ja) * | 2011-10-21 | 2013-12-11 | ファイザー・リミテッド | 新規な塩および医学的使用 |
| US20140039004A1 (en) * | 2012-07-31 | 2014-02-06 | Ono Pharmaceutical Co., Ltd. | Method of treating of gastroesophageal reflux disease |
| PL3138633T3 (pl) * | 2014-04-30 | 2019-05-31 | Ind Penalver Sl | Programowalna głowica koncentryczna do nakładania płynu na pokrywy o różnych kształtach |
| ES2821962T3 (es) * | 2015-11-13 | 2021-04-28 | Dae Woong Pharma | Bloqueador de canales de sodio |
| RU2659955C1 (ru) * | 2017-10-26 | 2018-07-04 | Галина Ильхамовна Лукина | Способ диагностики высоких гастроэзофагеальных рефлюксов |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4066636A (en) * | 1976-02-02 | 1978-01-03 | Fuji Photo Film Co., Ltd. | Method of hardening gelatin |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2419923A1 (de) * | 1973-04-28 | 1974-11-28 | Fujisawa Pharmaceutical Co | Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel |
| JPS5748534B2 (https=) | 1974-03-04 | 1982-10-16 | ||
| DE2555048A1 (de) * | 1975-12-06 | 1977-06-30 | Pfersee Chem Fab | Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen |
| JPH05293469A (ja) | 1992-04-17 | 1993-11-09 | Toda Constr Co Ltd | 滅菌精製水の製造方法およびその装置 |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| AU4431400A (en) * | 1999-05-12 | 2000-12-05 | Japan As Represented By President Of National Cancer Center | Anticancer agents containing ep1 antagonists as the active ingredient |
| AU6180600A (en) | 1999-07-29 | 2001-02-19 | Ono Pharmaceutical Co. Ltd. | Sulfonamide derivatives and remedies for allodynia |
| WO2002072145A1 (en) * | 2001-03-14 | 2002-09-19 | Ono Pharmaceutical Co., Ltd. | Remedies for depression containing ep1 antagonist as the active ingredient |
-
2002
- 2002-03-11 MX MXPA03008134A patent/MXPA03008134A/es active IP Right Grant
- 2002-03-11 IL IL15770102A patent/IL157701A0/xx unknown
- 2002-03-11 KR KR1020037011921A patent/KR100886854B1/ko not_active Expired - Fee Related
- 2002-03-11 EP EP02705096A patent/EP1369419B1/en not_active Expired - Lifetime
- 2002-03-11 AU AU2002238855A patent/AU2002238855B2/en not_active Ceased
- 2002-03-11 AT AT05109059T patent/ATE522513T1/de active
- 2002-03-11 RU RU2003127677/04A patent/RU2299202C2/ru not_active IP Right Cessation
- 2002-03-11 WO PCT/JP2002/002245 patent/WO2002072564A1/ja not_active Ceased
- 2002-03-11 HU HU0400155A patent/HU230056B1/hu not_active IP Right Cessation
- 2002-03-11 CN CNB028097904A patent/CN1294126C/zh not_active Expired - Fee Related
- 2002-03-11 DK DK02705096T patent/DK1369419T3/da active
- 2002-03-11 US US10/471,673 patent/US7235667B2/en not_active Expired - Fee Related
- 2002-03-11 CA CA2439604A patent/CA2439604C/en not_active Expired - Fee Related
- 2002-03-11 BR BR0208027-3A patent/BR0208027A/pt not_active IP Right Cessation
- 2002-03-11 JP JP2002571480A patent/JP3555620B2/ja not_active Expired - Fee Related
- 2002-03-11 DK DK05109059.5T patent/DK1612208T3/da active
- 2002-03-11 EP EP05109059A patent/EP1612208B1/en not_active Expired - Lifetime
- 2002-03-11 PL PL365100A patent/PL218750B1/pl unknown
- 2002-03-11 AT AT02705096T patent/ATE362924T1/de active
- 2002-03-11 DE DE60220255T patent/DE60220255T2/de not_active Expired - Lifetime
- 2002-03-11 CZ CZ20032452A patent/CZ304035B6/cs not_active IP Right Cessation
- 2002-03-11 PT PT02705096T patent/PT1369419E/pt unknown
- 2002-03-11 ES ES02705096T patent/ES2286230T3/es not_active Expired - Lifetime
- 2002-03-11 TW TW091104451A patent/TWI317359B/zh not_active IP Right Cessation
- 2002-03-11 NZ NZ528120A patent/NZ528120A/en not_active IP Right Cessation
- 2002-03-11 PT PT05109059T patent/PT1612208E/pt unknown
-
2003
- 2003-09-02 IL IL157701A patent/IL157701A/en not_active IP Right Cessation
- 2003-09-03 ZA ZA2003/06884A patent/ZA200306884B/en unknown
- 2003-09-10 NO NO20034007A patent/NO329682B1/no not_active IP Right Cessation
- 2003-12-24 JP JP2003427226A patent/JP3741120B2/ja not_active Expired - Fee Related
-
2005
- 2005-08-26 JP JP2005245763A patent/JP4432051B2/ja not_active Expired - Fee Related
- 2005-09-30 US US11/239,406 patent/US7629369B2/en not_active Expired - Fee Related
-
2009
- 2009-10-21 US US12/603,194 patent/US8088802B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4066636A (en) * | 1976-02-02 | 1978-01-03 | Fuji Photo Film Co., Ltd. | Method of hardening gelatin |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8088802B2 (en) | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | |
| JP5702392B2 (ja) | キサンチンオキシダーゼ阻害剤として効果的な新規化合物、その製造方法及びそれを含有する医薬組成物 | |
| KR20080040046A (ko) | 티아졸 유도체 | |
| KR20150018788A (ko) | 혈전색전성 질환의 치료를 위한 인자 ｘｉａ 억제제로서 치환된 피롤리딘 | |
| JPWO2002072145A1 (ja) | Ｅｐ１アンタゴニストを有効成分として含有するうつ病の治療剤 | |
| KR20100092909A (ko) | 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 | |
| WO2001055123A1 (en) | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | |
| AU2002308891B2 (en) | Novel heterocyclic derivatives and medicinal use thereof | |
| AU2002308889B2 (en) | Novel heterocyclic compound and medicinal use thereof | |
| ES2368334T3 (es) | Compuesto de n-fenilarilsulfonamida, composición farmacéutica que comprende el compuesto como principio activo, intermedio sintético para el compuesto y procedimientos para su preparación. | |
| JPH1017549A (ja) | 二環性芳香族アミジン誘導体 | |
| JPWO2001000613A1 (ja) | ベンズイミダゾール化合物及びそれを含む医薬 | |
| WO2025115896A1 (ja) | Ｅｐ４アゴニスト | |
| TW202132282A (zh) | 基質金屬蛋白酶(mmp)抑制劑及其使用方法 | |
| JPH10120568A (ja) | 糸球体腎炎予防治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20130201 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20140204 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20150130 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20160127 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20170227 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20170227 |